Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Novacyt   /   nieuws Novacyt

Aandeel Novacyt PSE:ALNOV.FR, FR0010397232

Laatste koers (eur) Verschil Volume
0,587   -0,017   (-2,81%) Dagrange 0,586 - 0,612 197.865   Gem. (3M) 360,6K

nieuws Novacyt

Volgen
225 Posts
Pagina: «« 1 ... 7 8 9 10 11 12 | Laatste | Omlaag ↓
  1. forum rang 10 voda 1 mei 2024 16:10
    Novacyt S.A.

    ("Novacyt", the "Company" or the "Group")

    DHSC application for summary judgment dismissed

    Paris, France, and Eastleigh and Manchester, UK - 1 May 2024 - Following the announcement on 19 April 2024, Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, notes the judgment by Mrs Justice Jefford following the Pre-Trial Review heard on 30 April 2024. Mrs Justice Jefford has dismissed the application by the Department of Health and Social Care ("DHSC") for summary judgment.

    The Pre-Trial Review has now concluded, and the trial hearing has been listed to commence on 10 June 2024, and finish on 4 July 2024. The Company expects the court to reserve judgment, meaning that the outcome of the trial will not be known on 4 July 2024.

    www.voxmarkets.co.uk/rns/announcement...
  2. RAMO 22 mei 2024 16:14
    www.research-tree.com/newsfeed/articl...

    Novacyt S.A.

    ("Novacyt", the "Company" or the "Group")

    Notice of Results and Annual General Meeting

    Paris, France, and Eastleigh and Manchester, UK - 20 May 2024 - Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces that it will report its audited financial results for the year ended 31 December 2023 on Thursday, 30 May 2024.

    The Company also announces that its Annual General Meeting ("AGM") will be held at 2pm CEST/1pm BST on Wednesday, 26 June 2024 as an open virtual meeting. Further details of the AGM will be provided to shareholders in due course.

    Investor webinar

    An investor webinar presentation by Lyn Rees, Chief Executive Officer, and Steve Gibson, Chief Financial Officer, relating to the FY 2023 results will take place at 11.00am BST on Thursday, 30 May 2024.

    The webinar is open to all existing and potential investors, and will consist of a presentation followed by a Q&A session, held on the Investor Meet Company platform. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9.00am the day before the meeting or at any time during the live presentation. Automated French subtitling will be available throughout the presentation.
  3. forum rang 10 voda 30 mei 2024 11:20
    30 May NCYT – Full Year 2023 Results (30.05.2024)
    in Board, News

    Novacyt S.A.

    (“Novacyt”, the “Company” or the “Group”)

    Full Year 2023 results
    Integration of Yourgene Health remains on track
    Laying the foundations for future growth

    Paris, France, and Eastleigh and Manchester, UK – 30 May 2024 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces its audited results for the year ended 31 December 2023. The results include almost four months’ trading of Yourgene Health Limited (formerly plc) (“Yourgene”) following its acquisition by the Group, which completed on 8 September 2023.

    Operational Highlights (including post year-end and Yourgene 2023 activities pre-acquisition)

    Completed the strategic acquisition of Yourgene, significantly enhancing Novacyt’s global diagnostics business, adding scale and diversification to accelerate long-term growth.
    Lyn Rees and John Brown CBE joined the Novacyt Board as Executive and Non-Executive Director respectively.
    Lyn Rees appointed Chief Executive Officer following a six-year tenure as CEO of Yourgene Health plc, bringing over 28 years’ global healthcare leadership and commercial experience.
    Steve Gibson appointed CFO, and to join the Board along with Dr Jo Mason, CSO, subject to shareholder approval.
    IVDR certification: received first IVDR accreditation for the Yourgene DPYD genotyping assay for chemotoxicity in chemotherapy patients; submitted application for Cystic Fibrosis quantitative fluorescence PCR (QF-PCR) test.
    Yourgene became a compatible partner of PacBio, a leading global developer of sequencing technology, supporting the use of the LightBench™ instrument (Ranger® Technology) to its global customer base.
    Yourgene launched MagBench™ automated DNA extraction platform for NIPT workflows in Asia-Pacific and the Middle East.
    Launch of the Primer Design Co-Prep ES instrument, providing automated DNA and RNA extraction using Primer Design assays, for use in multiple applications.
    Primer Design launched a range of “complete” assays, including customised mastermix reagent for RUO customers.

    Financial Highlights

    Acquired the AIM-listed company Yourgene and its subsidiaries for an all-cash consideration of £16.7m on 8 September 2023.
    Group statutory revenue for FY2023 was £11.6m, in line with guidance, of which £0.6m relates to COVID-19 (FY2022*: £21.0m, of which £14.7m related to COVID-19).
    Group statutory revenue for the non-COVID-19 portfolio of £11.0m represents circa 95% of total revenue (FY2022*: £6.3m).
    Group gross profit totalled £3.7m (32%) in FY2023 (FY2022: £5.7m (27%)). This was reduced predominantly as a result of providing for all remaining COVID-19 associated stock, in addition to writing off stock that had not been provided for previously. Excluding the impact of these items, the Group gross profit margin would be in excess of 60%.
    Group EBITDA loss in FY2023 totalled £13.7m before exceptional items (FY2022: £13.5m loss).
    Loss after tax increased to £28.3m in FY2023 (FY2022: £25.7m loss).
    Completed cost savings actions that will deliver over £4.0m of bottom-line improvement, the Group is tracking ahead of schedule on the targeted synergies to be achieved from the Yourgene acquisition.
    Cash position at 31 December 2023 was £44.1m (2022: £87.0m), reflecting the cash consideration and associated costs of the acquisition of Yourgene. The Group remains debt free.

    *excludes any Yourgene revenue as pre-acquisition

    Commenting on the results Lyn Rees, CEO of Novacyt, said: “2023 was a transitional year for Novacyt, during which the Group completed the acquisition of Yourgene, a significant milestone that has enhanced our global diagnostics capabilities, diversified our product portfolio and increased the scale of our non-COVID-19 revenues.

    “We continue to focus all efforts towards working as a single business so that the reorganisation of the Group and the resulting synergies will leave us well placed to deliver future growth. We remain focused on driving the global sales of our key clinical and instrumentation products, while also rebuilding our RUO business. The Board believes that investment in R&D combined with our commercial strength is key to achieving long-term growth and we are increasingly well-placed to execute our business strategy.”

    novacyt.com/ncyt-full-year-2023-resul...
  4. forum rang 10 voda 11 juni 2024 09:18
    11 Jun NCYT – Settlement of the dispute with the DHSC (11.06.2024)
    in Board, News
    Novacyt S.A.

    (“Novacyt”, the “Company” or the “Group”)

    Settlement of the dispute with the DHSC

    Paris, France, and Eastleigh and Manchester, UK – 11 June 2024 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces that the parties have reached a commercial settlement of all claims and counterclaims in the High Court proceedings previously disclosed by the Company, on terms that the Company pays £5 million to the Department of Health and Social Care (“DHSC”). The trial listed to begin this week will therefore not take place. Neither party has made any admission of liability or wrongdoing in respect of the claim or counterclaim or otherwise.
    This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014, as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018. The person responsible for arranging for the release of this announcement on behalf of the Company is Steve Gibson.

    Contacts

    Novacyt SA

    novacyt.com/investors

    Lyn Rees, Chief Executive Officer

    Steve Gibson, Chief Financial Officer

    Via Walbrook PR

    SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

    +44 (0)20 3470 0470

    Matthew Johnson / Charlie Bouverat (Corporate Finance)

    Vadim Alexandre / Rob Rees (Corporate Broking)

    Deutsche Numis (Joint Broker)

    +44 (0)20 7260 1000

    Freddie Barnfield / Duncan Monteith / Michael Palser

    Allegra Finance (French Listing Sponsor)

    Rémi Durgetto / Yannick Petit

    +33 (1) 42 22 10 10
    r.durgetto@allegrafinance.com / y.petit@allegrafinance.com

    Walbrook PR (Financial PR & IR)

    Stephanie Cuthbert / Paul McManus /

    Phillip Marriage / Alice Woodings

    +44 (0)20 7933 8780 or novacyt@walbrookpr.com

    +44 (0)7796 794 663/ +44 (0)7980 541 893

    + 44 (0)7867 984 082 / +44 (0)7407 804 654



    About Novacyt Group (www.novacyt.com)

    Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.

    The Company is divided into three business segments:

    Clinical
    Broad portfolio of human clinical in vitro diagnostic products, workflows and services focused on three therapeutic areas:
    • Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests
    • Precision Medicine: DPYD genotyping assay
    • Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel

    Instrumentation
    Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including:
    • Ranger® Technology: automated DNA sample preparation and target enrichment technology
    • MyGo: real-time quantitative PCR (qPCR) instruments

    Research Use Only
    Range of services for the life science industry:
    • Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry
    • Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES)

    Novacyt is headquartered in Vélizy-Villacoublay in France with offices in the UK (in Stokesley, Eastleigh and Manchester), Taipei, Singapore, the US and Canada and has a commercial presence in over 65 countries. The Company is listed on the London Stock Exchange’s AIM market (“NCYT”) and on the Paris Stock Exchange Euronext Growth (“ALNOV”).

    For more information, please refer to the website: www.novacyt.com

    NCYT – Settlement of the dispute with the DHSC (11.06.2024) pdf
225 Posts
Pagina: «« 1 ... 7 8 9 10 11 12 | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee